semagacestat
Sign in to saveAlso known as LY-450139, LY450139
Semagacestat (LY-450139) was a candidate drug for a causal therapy against Alzheimer's disease. It was originally developed by Eli Lilly and Elan, and clinical trials were conducted by Eli Lilly. Phase III trials included over 3000 patients, but in August 2010, a disappointing interim analysis, in which semagacestat performed worse than the placebo, led to the trials being stopped.
~5 min read
Encyclopedic overview
4 sectionsContents
- Mechanism of action
- Clinical trials
- Issues
- References
{{Infobox drug | Verifiedfields = changed | Watchedfields = changed | verifiedrevid = 443328897 | IUPAC_name = (2S)-2-Hydroxy-3-methyl-N-((1S)-1-methyl-2-{[(1S)-3-methyl-2-oxo-2,3,4,5-tetrahydro-1H-3-benzazepin-1-yl]amino}-2-oxoethyl)butanamide | image = Semagacestat.svg | image_class = skin-invert-image
| tradename = | pregnancy_AU = | pregnancy_US = | pregnancy_category = | legal_AU = | legal_CA = | legal_UK = | legal_US = | legal_status = Development terminated | routes_of_administration = By mouth
Excerpted from Wikipedia’s “semagacestat” article, available under the CC BY-SA 4.0 licence.